UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 242

Sortiert nach

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Journal of clinical oncology, 2021-12, Vol.39 (35), p.3959-3977

2021

Volltextzugriff (PDF)

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

Breast cancer research and treatment, 2020-06, Vol.181 (3), p.487-497

2020

Volltextzugriff (PDF)

Unmet challenges in systemic therapy for early stage breast cancer

Breast (Edinburgh), 2022-03, Vol.62 (Suppl 1), p.S67-S69

Burstein, Harold J.

2022

Volltextzugriff (PDF)

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Journal of clinical oncology, 2016-09, Vol.34 (25), p.3069-3103

2016

Volltextzugriff (PDF)

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Journal of clinical oncology, 2017-09, Vol.35 (27), p.3113-3122

2017

Volltextzugriff (PDF)

Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease

Journal of clinical oncology, 2008-02, Vol.26 (5), p.814-819

2008

Volltextzugriff (PDF)

Aromatase inhibitor-associated arthralgia syndrome

Breast (Edinburgh), 2007-06, Vol.16 (3), p.223-234

Burstein, Harold J

2007

Volltextzugriff (PDF)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

NPJ breast cancer, 2023-03, Vol.9 (1), p.15-15, Article 15

2023

Volltextzugriff (PDF)

Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review

Progress in cardiovascular diseases, 2010-09, Vol.53 (2), p.94-104

2010

Volltextzugriff (PDF)

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply

The New England journal of medicine, 2021-03, Vol.384 (12), p.1176-1177

Burstein, Harold J

2021

Volltextzugriff (PDF)

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Cancer, 2003-06, Vol.97 (12), p.2972-2977

2003

Volltextzugriff (PDF)

Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer

Hematology/oncology clinics of North America, 2023-02, Vol.37 (1), p.xiii-xvi

Burstein, Harold J.

2023

Volltextzugriff (PDF)

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

Clinical cancer research, 2007-02, Vol.13 (4), p.1198-1207

2007

Volltextzugriff (PDF)

NCCN task force report: management of neuropathy in cancer

Journal of the National Comprehensive Cancer Network, 2009-09, Vol.7 Suppl 5, p.S1

2009

Volltextzugriff (PDF)

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Journal of clinical oncology, 2019-02, Vol.37 (5), p.423-438

2019

Volltextzugriff (PDF)

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Journal of clinical oncology, 2023-06, Vol.41 (18), p.3423-3425

2023

Volltextzugriff (PDF)

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Journal of clinical oncology, 2003-08, Vol.21 (15), p.2889-2895

2003

Volltextzugriff (PDF)

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer

JAMA oncology, 2016-01, Vol.2 (1), p.29

2016

Volltextzugriff (PDF)

Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans

Hypertension (Dallas, Tex. 1979), 2011-07, Vol.58 (1), p.85-92

2011

Volltextzugriff (PDF)

Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations

JAMA : the journal of the American Medical Association, 2021-01, Vol.325 (1), p.36

2021

Volltextzugriff (PDF)

Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit

Breast (Edinburgh), 2019-11, Vol.48 Suppl 1, p.S89-S91

Burstein, Harold J

2019

Volltextzugriff (PDF)

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2179-2182

2012

Volltextzugriff (PDF)

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1689-1701

2016

Volltextzugriff (PDF)

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)

NPJ breast cancer, 2022-11, Vol.8 (1), p.127-9, Article 127

2022

Volltextzugriff (PDF)

Past, present, and future challenges in breast cancer treatment

Journal of clinical oncology, 2014-07, Vol.32 (19), p.1979-1986

2014

Volltextzugriff (PDF)

1 – 25 von 242

Suche als RSS-Feed

Aktive Filter

ThemaChemotherapy

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(235)
Mit Volltextzugriff
(164)

Publikationsform

Sprache

Englisch
(242)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Humans
(165)
Life Sciences & Biomedicine
(150)
Science & Technology
(150)
Oncology
(133)
Female
(120)
Breast Neoplasms - Drug Therapy
(72)
Breast Cancer
(39)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(38)
Chemotherapy, Adjuvant
(34)
Breast Neoplasms - Pathology
(33)
Breast Neoplasms - Therapy
(32)
Neoplasm Staging
(30)
Adult
(29)
Middle Aged
(28)
Antineoplastic Agents - Therapeutic Use
(22)
Aged
(21)
Receptor, Erbb-2 - Metabolism
(19)
Treatment Outcome
(18)
Breast Neoplasms - Metabolism
(17)
Hematology, Oncology And Palliative Medicine
(17)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

Unmet challenges in systemic therapy for early stage breast cancer

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease

Aromatase inhibitor-associated arthralgia syndrome

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

NCCN task force report: management of neuropathy in cancer

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer

Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans

Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations

Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)

Past, present, and future challenges in breast cancer treatment

Aktive Filter

Suchergebnisse filtern